Stock Forecast

  IsoPlexis Corporation ( ISO) Stock. Should you Buy or Sell?    $ 2.18

0.06 (2.68 %)



IsoPlexis Corporation Analysis

Updated on 10-09-2022
Symbol ISO
Price $2.18
Beta 0.000
Volume Avg. $86.17 thousand
Market Cap $85.9 M
52 Week Range $1.62 - $16.95


IsoPlexis Corporation opened the day at $2.18 which is +'2.68 % on yesterday's close. IsoPlexis Corporation has a 52 week high of $16.95 and 52 week low of $1.62, which is a difference of $15.33. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $85.9 M and total net profit is $17258 which means the company is trading at 4977.67 times profit to market capitalization. Theoretically, if you were to buy IsoPlexis Corporation for $85.9 M, it would take 15 years to get your money back. IsoPlexis Corporation are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




IsoPlexis Corporation Stock Forecast - Is IsoPlexis Corporation a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreBuy
PE ScoreSell
PB ScoreBuy
Overall RecommendationNeutral

Growth and Value


PE Ratio 0.222
Dividend Yiel 0.000
Net Profit Margin -6.172


Valuing IsoPlexis Corporation


Price Book Value Ratio 0.941 Price To Book Ratio 0.941
Price To Sales Ratio 3.725 Price Earnings Ratio -0.603


How liquid is IsoPlexis Corporation


Current Ratio 10.204
Quick Ratio 6.593


Debt


Debt Ratio 0.408 Debt Equity Ratio 0.689
Long Term Debt To Capitalization 0.360 Total Debt To Capitalization 0.000



Latest news about IsoPlexis Corporation


IsoPlexis to Participate in the Morgan Stanley Global Healthcare Conference

BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Date : 31/08/2022

IsoPlexis Corporation (ISO) CEO Sean Mackay on Q2 2022 Results Earnings Call Transcript

IsoPlexis Corporation (NASDAQ:ISO ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Carrie Mendivil - IR Sean Mackay - CEO John Strahley - CFO Conference Call Participants Vijay Kumar - Evercore Max Masucci - Cowen Puneet Souda - SVB Leerink Tejas Savant - Morgan Stanley Operator Good morning ladies and gentlemen, thank you for standing by. And welcome to IsoPlexis' Second Quarter 2022 Earnings Conference Call.

Date : 10/08/2022

IsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022

BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Date : 21/07/2022

IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional Proteomics at AACR 2022

IsoLight and Duomic Technologies Detect T Cell Receptors and Highly Multiplexed Functional Cytokines from the Same Single Cells to Advance Cancer Immunology Discovery IsoLight and Duomic Technologies Detect T Cell Receptors and Highly Multiplexed Functional Cytokines from the Same Single Cells to Advance Cancer Immunology Discovery

Date : 08/04/2022

IsoPlexis' (ISO) CEO Sean Mackay on Q4 2021 Results - Earnings Call Transcript

IsoPlexis' (ISO) CEO Sean Mackay on Q4 2021 Results - Earnings Call Transcript

Date : 02/03/2022





About IsoPlexis Corporation


CEO :
Sector : Healthcare
Industry : Medical Devices

Website : https://isoplexis.com

Exchange : NASDAQ Global Select

Description :

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.


My Newsletter

Sign Up For Updates & Newsletters